Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 359,623
  • Shares Outstanding, K 46,224
  • Annual Sales, $ 100,360 K
  • Annual Income, $ -32,890 K
  • 60-Month Beta 0.61
  • Price/Sales 3.50
  • Price/Cash Flow N/A
  • Price/Book 7.05
Trade CTMX with:

Options Overview

Details
  • Implied Volatility 140.95%
  • Historical Volatility 71.36%
  • IV Percentile 72%
  • IV Rank 19.74%
  • IV High 426.63% on 03/16/20
  • IV Low 70.70% on 12/16/20
  • Put/Call Vol Ratio 0.23
  • Today's Volume 352
  • Volume Avg (30-Day) 207
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 1,723
  • Open Int (30-Day) 1,457

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.26
  • Number of Estimates 5
  • High Estimate -0.06
  • Low Estimate -0.37
  • Prior Year 0.26
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.01 +10.98%
on 03/05/21
9.42 -17.41%
on 02/16/21
-0.26 (-3.23%)
since 02/05/21
3-Month
6.43 +21.00%
on 01/04/21
9.42 -17.41%
on 02/16/21
+0.38 (+5.14%)
since 12/04/20
52-Week
3.60 +116.41%
on 03/16/20
15.44 -49.61%
on 05/13/20
+0.68 (+9.58%)
since 03/05/20

Most Recent Stories

More News
CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock?

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CTMX : 7.78 (+2.37%)
Moving Average Crossover Alert: CytomX Therapeutics (CTMX)

CytomX Therapeutics (CTMX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

CTMX : 7.78 (+2.37%)
CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

-Broad advancement of clinical pipeline-

CTMX : 7.78 (+2.37%)
CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its...

CTMX : 7.78 (+2.37%)
CytomX Therapeutics Announces New Employment Inducement Grant

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its...

CTMX : 7.78 (+2.37%)
CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its...

CTMX : 7.78 (+2.37%)
Continued Research Grants New Options in Cancer Treatment

, /PRNewswire/ -- The growing prevalence of cancer all over the globe is a major obstacle to overcome. In 2020, an estimated 1,806,590 new cases of cancer were diagnosed in alone and 606,520 people...

SBFM : 0.0950 (+9.45%)
CRDF : 9.72 (+5.88%)
TRIL : 10.03 (-2.15%)
SURF : 7.50 (-0.40%)
CTMX : 7.78 (+2.37%)
CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology...

CTMX : 7.78 (+2.37%)
UPDATE - CytomX Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has...

JPM : 150.91 (+0.23%)
CTMX : 7.78 (+2.37%)
CytomX Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has...

JPM : 150.91 (+0.23%)
CTMX : 7.78 (+2.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 8.81
2nd Resistance Point 8.29
1st Resistance Point 8.04
Last Price 7.78
1st Support Level 7.27
2nd Support Level 6.75
3rd Support Level 6.50

See More

52-Week High 15.44
Fibonacci 61.8% 10.92
Fibonacci 50% 9.52
Fibonacci 38.2% 8.12
Last Price 7.78
52-Week Low 3.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar